BR112022011758A2 - Terapêutica de câncer inibidor de cdk4/6 seletivo - Google Patents

Terapêutica de câncer inibidor de cdk4/6 seletivo

Info

Publication number
BR112022011758A2
BR112022011758A2 BR112022011758A BR112022011758A BR112022011758A2 BR 112022011758 A2 BR112022011758 A2 BR 112022011758A2 BR 112022011758 A BR112022011758 A BR 112022011758A BR 112022011758 A BR112022011758 A BR 112022011758A BR 112022011758 A2 BR112022011758 A2 BR 112022011758A2
Authority
BR
Brazil
Prior art keywords
cancer therapy
compounds
selective cdk4
cancer
cdk
Prior art date
Application number
BR112022011758A
Other languages
English (en)
Inventor
P Lisanti Michael
Sotgia Federica
Kangasmetsa Jussi
G Magalhães Luma
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of BR112022011758A2 publication Critical patent/BR112022011758A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

TERAPÊUTICA DE CÂNCER INIBIDOR DE CDK4/6 SELETIVO. Esta descrição descreve inibidores seletivos e potentes de CDK 4/6 que mostram inibição vantajosa do crescimento do câncer, mesmo em baixas concentrações. Esta classe de inibidores de CDK 4/6 anticancerígenos são compostos de pirrolopirimidina substituídos de fórmula 1A, tendo uma porção de ácido graxo. Estes compostos podem ser usados como compostos farmacêuticos para terapias anticancer, e são úteis para o tratamento, prevenção e/ou melhora do câncer.
BR112022011758A 2019-12-16 2020-12-15 Terapêutica de câncer inibidor de cdk4/6 seletivo BR112022011758A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962948498P 2019-12-16 2019-12-16
US202062966834P 2020-01-28 2020-01-28
PCT/IB2020/061972 WO2021124106A1 (en) 2019-12-16 2020-12-15 Selective cdk4/6 inhibitor cancer therapeutics

Publications (1)

Publication Number Publication Date
BR112022011758A2 true BR112022011758A2 (pt) 2022-08-30

Family

ID=76807266

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011758A BR112022011758A2 (pt) 2019-12-16 2020-12-15 Terapêutica de câncer inibidor de cdk4/6 seletivo

Country Status (13)

Country Link
US (1) US20230043357A1 (pt)
EP (1) EP4077331A4 (pt)
JP (1) JP2023507140A (pt)
KR (1) KR20220113985A (pt)
CN (1) CN114901666A (pt)
AU (1) AU2020405427A1 (pt)
BR (1) BR112022011758A2 (pt)
CA (1) CA3164617A1 (pt)
CR (1) CR20220343A (pt)
IL (1) IL293940A (pt)
MX (1) MX2022007487A (pt)
WO (1) WO2021124106A1 (pt)
ZA (1) ZA202207449B (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
PL2331547T3 (pl) * 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
MX2012011912A (es) * 2010-04-13 2012-11-16 Novartis Ag Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.

Also Published As

Publication number Publication date
EP4077331A1 (en) 2022-10-26
AU2020405427A1 (en) 2022-07-14
JP2023507140A (ja) 2023-02-21
CA3164617A1 (en) 2021-06-24
CR20220343A (es) 2023-02-28
ZA202207449B (en) 2023-12-20
KR20220113985A (ko) 2022-08-17
IL293940A (en) 2022-08-01
CN114901666A (zh) 2022-08-12
WO2021124106A1 (en) 2021-06-24
MX2022007487A (es) 2022-08-04
EP4077331A4 (en) 2023-12-27
US20230043357A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
WO2016106331A8 (en) Mutant idh1 inhibitors useful for treating cancer
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
BRPI0510059B8 (pt) inibidores da transcriptase reversa não-nucleosídica e seus usos
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
BR112022002520A2 (pt) Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
BR112019003710A2 (pt) inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7.
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
BR112021022255A2 (pt) Composto usado como inibidor de quinase e aplicação do mesmo
CR20210364A (es) Compuestos de quinolina como inhibidores de quinasas tam y met
BRPI1008000A2 (pt) composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto.
BR112022025012A2 (pt) Inibidores de quinase de nek7
MX2022011697A (es) Inhibidores de ciclofilina y usos de los mismos.
BR112022011758A2 (pt) Terapêutica de câncer inibidor de cdk4/6 seletivo
BR112022010054A2 (pt) Compostos heterocíclicos como inibidores de delta-5 dessaturase e métodos de uso